Helix BioPharma Corp. Closes Private Placement

Author's Avatar
Dec 05, 2020
Article's Main Image

RICHMOND HILL, ON / ACCESSWIRE / December 4, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $1,100,000.